Company / Cash & Equivalents
REGENXBIO Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$34.5M
FY2025
5-year range
$34.5M / $338.4M
FY2021-FY2025
Trend
-40.1%
vs FY2024
Sector context
#193 of 207
Health Care
What the data says
Among 207 Health Care companies, REGENXBIO Inc. is in the bottom 7% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $1M in FY2016 to $338M in FY2021.
Based on SEC 10-K filings.
$34M in FY2025 with a 5-year CAGR of -13.1%.
Remained stable around $34M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -29.2%
- 5-Year CAGR
- -13.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 207This company $34.5M Sector average $669.5M
▼
-94.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -13.1%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 40.1% year-over-year.
- Ranks #193 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -2.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $34.5M | -40.1% |
| FY2024 | $57.5M | +66.6% |
| FY2023 | $34.5M | -64.4% |
| FY2022 | $97.0M | -71.4% |
| FY2021 | $338.4M | +386.8% |
| FY2020 | $69.5M | -8.0% |
| FY2019 | $75.6M | +0.0% |
| FY2018 | $75.6M | +62.0% |
| FY2017 | $46.7M | +4062.0% |
| FY2016 | $1.1M | +0.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026